腹腔给药在腹膜纤维化防治中的应用  

Review of intraperitoneal administration for peritoneal fibrosis

作　　者：唐雅娜 丁劲松 

机构地区：[1]中南大学湘雅药学院,长沙410000

出　　处：《中南药学》2017年第11期1577-1581,共5页Central South Pharmacy

摘　　要：腹膜透析是一种供终末期肾病患者选择的肾脏替代疗法,但长期腹膜透析会导致腹膜纤维化,最终迫使患者退出腹透治疗。腹膜纤维化的药物预防和治疗是延长腹膜透析周期的关键。相比口服,腹腔给药使药物直接接触腹膜组织,或将取得更好的效果。本文就腹膜纤维化的形成、机制及药物干预进行综述,重点介绍腹腔给药在腹膜纤维化中的应用,并就此提出几点展望。Peritoneal dialysis is an alternative replacement therapy for patients with end-stage renal disease. However, long-term peritoneal dialysis may lead to peritoneal fibrosis, eventually causing patients to withdraw from peritoneal dialysis. Using drugs for prevention and treatment is the key way. Compared with oral administration （Po）, intraperitoneal administration （IP） direct drug delivery to the surface of the peritoneum. may have better effect. The formation, mechanism and drug treatment of peritoneal fibrosis were reviewed, highlighted the intraperitoneal therapy for peritoneal fibrosis.

关 键 词：腹膜纤维化 腹膜透析 预防和治疗 腹腔给药 

分 类 号：R277.5[医药卫生—中医学]